A metabolomic profile is associated with the risk of incident coronary heart disease
Anika A M Vaarhorst, Aswin Verhoeven, Claudia M Weller, Stefan Böhringer, Sibel Göraler, Axel Meissner, André M Deelder, Peter Henneman, Anton P M Gorgels, Piet A van den Brandt, Leo J Schouten, Marleen M van Greevenbroek, Audrey H H Merry, W M Monique Verschuren, Arn M J M van den Maagdenberg, Ko Willems van Dijk, Aaron Isaacs, Dorret Boomsma, Ben A Oostra, Cornelia M van Duijn, J Wouter Jukema, Jolanda M A Boer, Edith Feskens, Bastiaan T Heijmans, P Eline Slagboom, Anika A M Vaarhorst, Aswin Verhoeven, Claudia M Weller, Stefan Böhringer, Sibel Göraler, Axel Meissner, André M Deelder, Peter Henneman, Anton P M Gorgels, Piet A van den Brandt, Leo J Schouten, Marleen M van Greevenbroek, Audrey H H Merry, W M Monique Verschuren, Arn M J M van den Maagdenberg, Ko Willems van Dijk, Aaron Isaacs, Dorret Boomsma, Ben A Oostra, Cornelia M van Duijn, J Wouter Jukema, Jolanda M A Boer, Edith Feskens, Bastiaan T Heijmans, P Eline Slagboom
Abstract
Background: Metabolomics, defined as the comprehensive identification and quantification of low-molecular-weight metabolites to be found in a biological sample, has been put forward as a potential tool for classifying individuals according to their risk of coronary heart disease (CHD). Here, we investigated whether a single-point blood measurement of the metabolome is associated with and predictive for the risk of CHD.
Methods and results: We obtained proton nuclear magnetic resonance spectra in 79 cases who developed CHD during follow-up (median 8.1 years) and in 565 randomly selected individuals. In these spectra, 100 signals representing 36 metabolites were identified. Applying least absolute shrinkage and selection operator regression, we defined a weighted metabolite score consisting of 13 proton nuclear magnetic resonance signals that optimally predicted CHD. This metabolite score, including signals representing a lipid fraction, glucose, valine, ornithine, glutamate, creatinine, glycoproteins, citrate, and 1.5-anhydrosorbitol, was associated with the incidence of CHD independent of traditional risk factors (TRFs) (hazard ratio 1.50, 95% CI 1.12-2.01). Predictive performance of this metabolite score on its own was moderate (C-index 0.75, 95% CI 0.70-0.80), but after adding age and sex, the C-index was only modestly lower than that of TRFs (C-index 0.81, 95% CI 0.77-0.85 and C-index 0.82, 95% CI 0.78-0.87, respectively). The metabolite score was also associated with prevalent CHD independent of TRFs (odds ratio 1.59, 95% CI 1.19-2.13).
Conclusion: A metabolite score derived from a single-point metabolome measurement is associated with CHD, and metabolomics may be a promising tool for refining and improving the prediction of CHD.
Copyright © 2014 Mosby, Inc. All rights reserved.
Source: PubMed